XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.1

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Sales of Company's products

Sales of the Company’s products were as follows:

			Three Months Ended March 31,
			2021																		2020
($ in millions)			U.S.						Int’l						Total						U.S.						Int’l						Total
Pharmaceutical:
Oncology
Keytruda			$	2,181					$	1,718					$	3,899					$	1,906					$	1,378					$	3,284
Alliance revenue - Lynparza (1)			118						110						228						85						60						145
Alliance revenue - Lenvima (1)			85						44						130						90						38						128
Vaccines
Gardasil/Gardasil 9			313						604						917						461						636						1,097
ProQuad/M-M-R II/Varivax			333						117						449						333						102						435
Pneumovax 23			73						99						171						182						75						256
RotaTeq			118						41						158						140						82						222
Vaqta			25						9						34						30						30						60
Hospital Acute Care
Bridion			167						173						340						143						157						299
Prevymis			35						47						82						26						33						60
Noxafil			15						52						67						8						87						94
Primaxin			—						65						65						—						51						51
Cancidas			3						55						57						3						52						55
Invanz			4						52						57						6						59						64
Zerbaxa			(2)						(6)						(8)						20						16						37
Immunology
Simponi			—						214						214						—						215						215
Remicade			—						85						85						—						88						88
Neuroscience
Belsomra			18						61						79						27						53						79
Virology
Isentress/Isentress HD			71						138						209						75						170						245
Cardiovascular
Zetia			2						90						92						(2)						147						145
Vytorin			2						38						41						3						50						53
Atozet			—						112						112						—						122						122
Alliance revenue - Adempas (2)			68						6						74						49						5						53
Adempas			—						55						55						—						56						56
Diabetes
Januvia			348						461						809						355						419						774
Janumet			84						401						486						113						390						503
Women’s Health
Implanon/Nexplanon			141						42						183						149						45						195
NuvaRing			21						24						45						26						37						63
Diversified Brands
Singulair			4						102						107						5						151						155
Cozaar/Hyzaar			3						87						90						7						95						102
Arcoxia			—						56						56						—						70						70
Follistim AQ			25						27						52						21						21						41
Nasonex			2						41						43						6						65						71
Other pharmaceutical (3)			384						814						1,197						447						886						1,338
Total Pharmaceutical segment sales			4,641						6,034						10,675						4,714						5,941						10,655
Animal Health:
Livestock			157						662						819						162						577						739
Companion Animals			280						319						599						222						253						475
Total Animal Health segment sales			437						981						1,418						384						830						1,214
Other segment sales (4)			—						—						—						23						—						23
Total segment sales			5,078						7,015						12,093						5,121						6,771						11,892
Other (5)			58						(72)						(13)						16						149						165
			$	5,136					$	6,943					$	12,080					$	5,137					$	6,920					$	12,057

U.S. plus international may not equal total due to rounding.

(1)    Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).

(2)    Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).

(3)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.

(4)    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested in the first quarter of 2020.

(5)    Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.

Consolidated revenues by geographic area

Consolidated sales by geographic area where derived are as follows:

			Three Months Ended March 31,
($ in millions)			2021						2020
United States			$	5,136					$	5,137
Europe, Middle East and Africa			3,729						3,534
China			927						864
Asia Pacific (other than China and Japan)			751						728
Japan			730						811
Latin America			569						556
Other			238						427
			$	12,080					$	12,057

Reconciliation of segment profits to income before taxes

A reconciliation of segment profits to Income before taxes is as follows:

			Three Months Ended March 31,
($ in millions)			2021						2020
Segment profits:
Pharmaceutical segment			$	7,555					$	7,582
Animal Health segment			572						479
Other segment			—						1
Total segment profits			8,127						8,062
Other profits			(34)						139
Unallocated:
Interest income			11						25
Interest expense			(200)						(212)
Amortization			(534)						(410)
Depreciation			(358)						(377)
Research and development			(2,358)						(2,097)
Restructuring costs			(298)						(72)
Other unallocated, net			(894)						(1,220)
			$	3,462					$	3,838

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

+ Details

Name:	us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration